deltatrials
Completed PHASE3 NCT00000926

A Study of Nonoxynol-9 (N-9) and HIV Infection

Phase III Nonoxynol-9 and HIV Infection

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Conditions HIV Infections
Interventions Nonoxynol-9
Updated 6 times since 2017 Last updated: Oct 27, 2021 Completion: Feb 28, 2001

Listed as NCT00000926, this PHASE3 trial focuses on HIV Infections and remains completed. Sponsored by National Institute of Allergy and Infectious Diseases (NIAID), it has been updated 6 times since 2026, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Change History

6 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  3. Nov 2021 — Jul 2024 [monthly]

    Completed PHASE3

  4. Jan 2021 — Nov 2021 [monthly]

    Completed PHASE3

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE3

▶ Show 1 earlier version

  1. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE3

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • National Institute of Allergy and Infectious Diseases (NIAID)
Data source: National Institute of Allergy and Infectious Diseases (NIAID)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Research Triangle Park, United States